Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

FibroGen (NASDAQ:FGEN) Stock Crosses Above Fifty Day Moving Average – Here’s Why

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript

FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates

FibroGen to Report Third Quarter 2025 Financial Results

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript

FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

FibroGen to Report Second Quarter 2025 Financial Results

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

FibroGen Announces 1-for-25 Reverse Stock Split

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

FibroGen to Report First Quarter 2025 Financial Results

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

FibroGen sells China unit to AstraZeneca in deal worth $160 million

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates

FibroGen Reports Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

FibroGen Layoffs 2024: What to Know About the Latest FGEN Job Cuts

Why Is FibroGen (FGEN) Stock Down 44% Today?

FibroGen to Report Second Quarter 2024 Financial Results

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

7 Penny Biotech Stocks to Triple Your Investment

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

FibroGen to Participate in Upcoming Investor Conferences

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

FibroGen Reports First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer